Enliven Therapeutics, Inc.

NASDAQ:ELVN

Biotechnology

Healthcare
$44.89 -0.27%

-$0.12 today

Market cap
$3.30B
Beta
0.40
P/E (TTM)
-28.4
EPS (TTM)
-$1.57
52W Low $14.79High $48.53

Volume 0.75M

Average 1.35M

ELVN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Enliven Therapeutics, Inc.NASDAQ: ELVN

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 77.98M shares rose 25.6% year over year, ahead of the +23.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 17.8% from the prior quarter. Over 3 fiscal years it compounded at +108.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25.6% holds above the trailing-twelve-month pace of +23.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
77.98M+17.8% QoQ
Last fiscal yearDec 2025
56.66M+20.4% YoY
LTMSep 2026
65.9M+23.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.6%——
1 year+20.4%——
3-year CAGR+108.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
56.66M USD
Year-over-year change
+20.4%
4-year CAGR
+64.1%

Weighted Avg Shares vs competitors

How ELVN compares with its peers on the latest reported figures

  • ELVN's LTM Sep 2026 weighted avg shares of 65.9M shares is the 8th highest of the 11 companies compared; the peer median is 137.13M shares.
  • Its year-over-year change of +23.1% is the 2nd highest of 11, against a peer median of +4.9%.
  • Over three fiscal years its annual growth of +108.5% compares with a peer median of +12.5%.
ELVN Competitors Peer median
Weighted Avg Shares for ELVN and competitors
Company Period LTM YoY 3-year CAGR
NUVBNuvation Bio Inc.LTM Jun 2026345.71M +7.2%+16.4%
EXELExelixis, Inc.LTM Jul 2026262.28M -6.5%-5.5%
INCYIncyte CorporationLTM Jun 2026198.21M +2.5%-4.2%
RVMDRevolution Medicines, Inc.LTM Jun 2026197.09M +10.9%+33.1%
RLAYRelay Therapeutics, Inc.LTM Jun 2026181.67M +12.1%+15.2%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
ELVNEnliven Therapeutics, Inc.LTM Sep 202665.9M +23.1%+108.5%
TYRATyra Biosciences, Inc.LTM Mar 202660.14M +2.0%+12.5%
CGEMCullinan Therapeutics, Inc.LTM Mar 202659.11M +2.4%+9.3%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
Peer median (excluding ELVN) 137.13M+4.9%+12.5%

Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000263K
Gross Profit0000(263K)
Gross Margin—————
Research & Development20.47M31.02M64.57M80.78M85.86M
Selling, General & Admin4.29M7.77M18.96M23.78M33.8M
Operating Expenses24.76M38.79M83.53M104.55M119.4M
Depreciation & Amortization115K215K297K317K263K
EBITDA(24.63M)(37.45M)(71.29M)(88.48M)(103.43M)
EBITDA Margin—————
Operating Income(24.76M)(38.79M)(83.53M)(104.55M)(119.66M)
Operating Margin—————
Interest Income22K1.13M11.97M14.89M16.01M
Interest Expense00000
Other Income / Expenses22K1.13M11.95M15.76M15.96M
Income Before Tax(24.74M)(37.66M)(71.58M)(88.79M)(103.69M)
Pre-Tax Margin—————
Income Tax Expense000232K0
Net Income(24.74M)(37.66M)(71.58M)(89.02M)(103.69M)
Net Margin—————
EPS (Basic)(3.17)(6.03)(2.01)(1.89)(1.83)
EPS (Diluted)(3.17)(6.03)(2.01)(1.89)(1.83)
Weighted Avg Shares7.81M6.25M35.55M47.07M56.66M
Weighted Avg Shares (Diluted)7.82M6.25M35.55M47.07M56.66M

Enliven Therapeutics, Inc.

NASDAQ:ELVN

Intrinsic Alpha fair value

Locked

Current Price

$44.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.